BiotechTube
CorVivo

CorVivo

San Diego, United States· Est.
corvivocardio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

CorVivo is a clinical-stage biotech company pioneering a regenerative medicine platform for cardiovascular applications. Its core technology is a proprietary extracellular matrix (ECM)-derived biomaterial that acts as a scaffold to facilitate the body's own repair processes for heart and vascular tissue. The company appears to be in the clinical development phase, targeting significant unmet needs in cardiac surgery and structural heart disease. As a private entity, it is likely funded by venture capital and is building its clinical and commercial strategy.

Cardiovascular

Technology Platform

Proprietary extracellular matrix (ECM)-based biomaterial platform designed as an acellular scaffold to recruit patient's own cells and facilitate regeneration of functional cardiovascular tissue.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The global shift towards regenerative medicine in cardiovascular care presents a massive opportunity to replace inert synthetic implants with bioactive, resorbable solutions.
High unmet needs in pediatric congenital heart surgery and complex adult re-operative surgery provide clear clinical entry points.
Success could position the company as an attractive acquisition target for large medtech firms.

Risk Factors

The company faces significant clinical trial risk, as regenerative outcomes are complex to measure and must prove superiority over standards of care.
Achieving FDA PMA approval is a high-bar, costly, and lengthy process.
Post-approval, surgeon adoption and securing favorable insurance reimbursement are major commercialization hurdles.

Competitive Landscape

CorVivo operates in a competitive space with large, established medical device companies (e.g., Abbott, Edwards Lifesciences, Getinge) offering traditional patches and grafts, and other biotech firms developing ECM-based products (e.g., LeMaitre Vascular, Aziyo Biologics). Differentiation hinges on demonstrating superior regenerative capability and long-term clinical outcomes in well-designed trials.

More companies in Regenerative Medicine →More companies in United States →